These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31354106)

  • 21. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
    Blenkinsop A; Parmar MK; Choodari-Oskooei B
    Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A flexible futility monitoring method with time-varying conditional power boundary.
    Ying Zhang ; Clarke WR
    Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
    Li X; Herrmann C; Rauch G
    BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When inferiority meets non-inferiority: implications for interim analyses.
    Bratton DJ; Williams HC; Kahan BC; Phillips PP; Nunn AJ
    Clin Trials; 2012 Oct; 9(5):605-9. PubMed ID: 22796636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-stage response adaptive randomization designs for multi-arm trials with binary outcome.
    Lu X; Shan G
    J Biopharm Stat; 2024 Jul; 34(4):526-538. PubMed ID: 37452825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-stage designs with small sample sizes.
    Kieser M; Rauch G; Pilz M
    J Biopharm Stat; 2023 Jan; 33(1):53-59. PubMed ID: 35612521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
    Barrado LG; Burzykowski T
    Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Group sequential multi-arm multi-stage survival trial design with treatment selection.
    Wu J; Li Y
    J Biopharm Stat; 2024 Jul; 34(4):453-468. PubMed ID: 37455424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
    Sambucini V
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group sequential designs in pragmatic trials: feasibility and assessment of utility using data from a number of recent surgical RCTs.
    Parsons NR; Stallard N; Parsons H; Haque A; Underwood M; Mason J; Khan I; Costa ML; Griffin DR; Griffin J; Beard DJ; Cook JA; Davies L; Hudson J; Metcalfe A
    BMC Med Res Methodol; 2022 Oct; 22(1):256. PubMed ID: 36183085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Covariate adjustment in Bayesian adaptive randomized controlled trials.
    Willard J; Golchi S; Moodie EE
    Stat Methods Med Res; 2024 Mar; 33(3):480-497. PubMed ID: 38327082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
    Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
    Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial.
    Choodari-Oskooei B; Thwin SS; Blenkinsop A; Widmer M; Althabe F; Parmar MK
    Clin Trials; 2023 Feb; 20(1):71-80. PubMed ID: 36647713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.